Verapamil 50 mg/mL oral suspension

Opaque suspension.

References: [1]

Non-dihydropyridine calcium-channel blocker with cardiovascular effects.
Active-drug context from another product’s labelling; it does not establish stability or dosing of this compounded preparation.

References: [2]

Final-product visual inspection. The institutional sheet gives no specific numerical limits.

References: [1]

For the finished product the source specifies:
Tight, light-resistant plastic container. Source prefers refrigeration and permits room temperature, without a numerical range.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

Complete formula-specific PPE is not specified. Select gloves, eye protection and exposure controls using the exact materials’ SDS and the local risk assessment.
Supplementary AEMPS framework: clean long-sleeved laboratory clothing, hair covering and dedicated footwear/overshoes. Powder handling requires suitable eye/respiratory protection; change gloves with activity or damage. Select the exact type/material using SDS and risk assessment.

References: [1] · [3]

A complete formula-specific hazard classification is not established. Assess potency, dust/aerosol, allergens, solvents, microbial risk and cross-contamination using the actual materials and process. Absence of a flag does not establish absence of hazard.

References: [1]

Follow the addition sequence, temperatures and times stated under Preparation Procedure. The specific monograph is not a complete qualification of the local facility/equipment.

References: [1]

Source period: 60 days. Local BUD remains to be assessed.
The source period applies to its exact composition, method and packaging. It is not this batch’s expiry date and cannot be transferred to another vehicle/strength. Calculate the actual date in the blank batch record.

References: [1]

No separate base is identified in the dependency register. Check any commercial vehicles/compound excipients listed in the formula.

References: [1]

Indicative checklist derived from the method: Balance of suitable resolution, Containers and mixing tools compatible with the materials, Capsule-filling equipment. Selection/qualification is defined locally.

References: [1]

Pulverise tablets or capsule contents. Levigate with a little of the specified vehicle, dilute progressively, transfer quantitatively with rinses, make to final volume and mix.

References: [1]

Use the source dosage form and vehicle. Tablet/capsule strengths follow their labels. Other products or vehicles are not automatically equivalent. The hospital index reports ongoing review against USP <795>.

References: [1]

Light-resistant plastic bottle as specified by the sheet.

References: [1]

Visually examine the final product against the stated appearance. The sheet supplies no validated assay method or numerical microbiological limit.

References: [1]

Tight, light-resistant plastic container. Source prefers refrigeration and permits room temperature, without a numerical range.

References: [1]

No additional special directions are established beyond the source route, storage and notes. Complete patient details, dose and directions from the prescription.

References: [1]

Verapamil 50 mg/mL oral suspension
Strength/variant: __________ Quantity: __________
Batch: __________ Prepared: __________ Use by: __________
Από του στόματος / Oral use
Dose/directions: __________
Storage: Tight, light-resistant plastic container. Source prefers refrigeration and permits room temperature, without a numerical range.
Shake before use.

References: [1]